Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

CIBA-GEIGY PROTESTING THOMPSON MEDICAL's DEXATRIM-15 CLAIMS of 15-hour duration of action, in a suit filed Sept. 6 in New York Federal Court. Ciba-Geigy cites a bioavailability study the firm commissioned that allegedly "demonstrates that Dexatrim-15 does not deliver 15 hours of appetite suppression." In fact, Ciba-Geigy asserts, "the study shows that the product's duration is less than 12 hours." The bioavailability study "also demonstrates that Dexatrim-15 does not meet FDA requirements of bioavailability," Ciba-Geigy maintains. "Since the amount of ]phenylpropanolamine[ released from the product is not equivalent to a standard ]phenylpropanolamine[ solution, such as two doses of 37.5 mg of ]phenylpropanolamine[ administered twice daily at six-hour intervals, the claim on the label of Dexatrim-15 that the product will deliver 75 mg of ]phenlpropanolamine[ to the user is false," Ciba-Geigy explained. Ciba-Geigy is requesting "preliminary and permanent injunctive relief enjoining ]Thompson Medical[ from claiming in any packaging, labeling, advertising or promotional materials that Dexatrim-15 provides 15-hour appetite control ]and[ that Dexatrim-15 delivers 75 mg of ]phenylpropanolamine[ to the user." Ciba-Geigy's complaint notes that Thompson Medical launched its Dexatrim-18 in September 1983, just after Ciba-Geigy launched its 16-hour sustained release phenylpropanolamine appetite suppressant Acutrim. Ciba-Geigy filed suit against the alleged 18-hour activity of Dexatrim-18 in December 1983 and Thompson Medical subsequently repacked Dexatrim as a 15-hour product. The Acutrim mfr. further cites a study conducted for Thompson Medical by Harris Labs that "shows that Dexatrim-15 does not deliver effective levels of appetite suppression for anywhere near 15 hours," Ciba-Geigy asserted. The firm obtained the Harris data in June when Thompson Medical filed, and then withdrew, a complaint against Ciba-Geigy's claims for Acutrim. According to Ciba-Geigy, Dexatrim-15 has a 13% market share of the OTC appetite suppressants. Ciba-Geigy maintains that "a substantial portion of the sales of Dexatrim-15 would have gone to Acutrim," which has a 14% share of the market, "had Dexatrim-15 not been in the market."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts